Activating mutations in the epidermal growth factorreceptor gene occur as early cancer-driving clonal events in a subset of patients with non-small cell lung cancer (NSCLC) and result in increased sensitivity to EGFR-tyrosine-kinase-inhibitors (EGFR-TKIs). This evidence concerns the gene EGFR and non-small cell lung carcinoma.